New antibody IMT-009 tested in patients with advanced cancers

NCT ID NCT05565417

Ongoing Disease control Sponsor: Immunitas Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand side effects, and get an early look at whether the drug can shrink tumors. Because it is a first-in-human study, the focus is on safety and dosing, not yet on proving effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMT-009 (a monoclonal antibody) given alone or with fruquintinib (a cancer pill)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced cancers that have stopped responding to standard therapies.
What could go wrong: This is a very early (Phase 1/2a) and small trial (67 people). The drug may not shrink tumors or could cause significant side effects. Results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Burkitt lymphoma colorectal cancer colorectal neoplasm diffuse large B-cell lymphoma esophageal cancer Esophageal Neoplasms follicular lymphoma head and neck squamous cell carcinoma Hodgkins lymphoma hormone receptor-positive breast cancer lymphoma non-small cell lung carcinoma skin squamous cell carcinoma small intestine carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BURKITT LYMPHOMA COLORECTAL CANCER CUTANEOUS SQUAMOUS CELL CARCINOMA DIFFUSE LARGE B-CELL LYMPHOMA ESOPHAGEAL CANCER FOLLICULAR LYMPHOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HODGKIN LYMPHOMA HORMONE RECEPTOR POSITIVE BREAST CARCINOMA NON-SMALL CELL LUNG CANCER SMALL BOWEL CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Site 3000

Nashville, Tennessee, 37203, United States
Site 4060

Sarasota, Florida, 34232, United States
Site 4100

Orlando, Florida, 32827, United States
Site 4500

Oklahoma City, Oklahoma, 73104, United States
Site 5000

Denver, Colorado, 80218, United States
Site 9112

Fairfax, Virginia, 22031, United States
Site 9280

Portland, Oregon, 97239, United States
Site 9384

Austin, Texas, 78705, United States
Site 9618

Tucson, Arizona, 85711, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.